10x Genomics $TXG Position Lifted by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in shares of 10x Genomics (NASDAQ:TXG) by 6.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,274,332 shares of the company’s stock after purchasing an additional 834,272 shares during the period. Vanguard Group Inc. owned about 10.66% of 10x Genomics worth $155,177,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Teacher Retirement System of Texas grew its holdings in 10x Genomics by 6.1% during the second quarter. Teacher Retirement System of Texas now owns 14,931 shares of the company’s stock worth $173,000 after acquiring an additional 858 shares during the period. Arizona State Retirement System boosted its holdings in shares of 10x Genomics by 3.0% during the third quarter. Arizona State Retirement System now owns 29,586 shares of the company’s stock worth $346,000 after purchasing an additional 872 shares during the period. Versant Capital Management Inc grew its stake in 10x Genomics by 3.3% in the third quarter. Versant Capital Management Inc now owns 29,364 shares of the company’s stock valued at $343,000 after purchasing an additional 945 shares in the last quarter. True Wealth Design LLC increased its position in 10x Genomics by 26.4% during the third quarter. True Wealth Design LLC now owns 4,534 shares of the company’s stock worth $53,000 after buying an additional 948 shares during the last quarter. Finally, Kera Capital Partners Inc. boosted its holdings in shares of 10x Genomics by 4.0% during the 3rd quarter. Kera Capital Partners Inc. now owns 32,269 shares of the company’s stock worth $377,000 after buying an additional 1,251 shares during the period. Institutional investors own 84.68% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 9,632 shares of 10x Genomics stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total transaction of $178,962.56. Following the transaction, the chief executive officer directly owned 1,061,924 shares of the company’s stock, valued at approximately $19,730,547.92. This trade represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 7,826 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total value of $145,407.08. Following the transaction, the insider owned 424,779 shares in the company, valued at approximately $7,892,393.82. The trade was a 1.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 26,426 shares of company stock valued at $490,995. Company insiders own 10.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on TXG shares. Barclays boosted their price target on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Leerink Partners decreased their price target on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research report on Tuesday, January 27th. TD Cowen increased their price target on shares of 10x Genomics from $18.00 to $19.00 and gave the company a “hold” rating in a research note on Friday, February 13th. UBS Group lifted their price objective on 10x Genomics from $14.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, February 20th. Finally, JPMorgan Chase & Co. raised their price target on 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $18.46.

10x Genomics Stock Down 2.2%

Shares of TXG opened at $22.62 on Wednesday. The business has a 50-day simple moving average of $19.58 and a two-hundred day simple moving average of $16.23. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $23.56. The stock has a market cap of $2.89 billion, a PE ratio of -64.63 and a beta of 2.20.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. The company had revenue of $166.03 million for the quarter, compared to analyst estimates of $160.35 million. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.40) earnings per share. On average, equities research analysts expect that 10x Genomics will post -1.43 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.